BlackRock Advisors’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

BlackRock Advisors’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-14,312	Closed	-$1K	–	3809
2016 Q3	$1K	Hold	14,312	–	–	﹤0.01%	3707
2016 Q2	$5K	Hold	14,312	–	–	﹤0.01%	3676
2016 Q1	$5K	Hold	14,312	–	–	﹤0.01%	3680
2015 Q4	$6K	Buy	+14,312	New	+$6.78K	﹤0.01%	3707

Other funds holding PVCT

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

HFBOT

Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

BlackRock Advisors's PVCT Position: Q4 2016 in Review

BlackRock Advisors sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q4 2016, closing a stake of 14,312 shares — an estimated $1K sold.

BlackRock Advisors first reported a position in PVCT in Q4 2015 and held it in 4 quarters. The position peaked at $6K in Q4 2015. 8 funds tracked by Wall St. Rank hold PVCT as of Q4 2016.

BlackRock Advisors reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q4 2016 after selling out during the quarter.
BlackRock Advisors sold 14,312 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q4 2016, an estimated $1K.
BlackRock Advisors first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q4 2015 and held it in 4 quarters.
BlackRock Advisors's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $6K in Q4 2015.
8 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.